Efficacy and safety of QMF149 vs. salmeterol xinafoate/fluticasone propionate in patients with COPD

Update Il y a 4 ans
Reference: EUCTR2012-001172-12

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The purpose of this study is to explore the efficacy of QMF149 (150/160 μg o.d.) delivered via Concept1 device compared with salmeterol xinafoate/fluticasone propionate (50/500 μg b.i.d.) delivered via Accuhaler® in patients with COPD.


Inclusion criteria

  • COPD